Modelling population-level impact to inform target product profiles for childhood malaria vaccines

BACKGROUND: The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogan, Alexandra B., Winskill, Peter, Verity, Robert, Griffin, Jamie T., Ghani, Azra C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044028/
https://www.ncbi.nlm.nih.gov/pubmed/30001708
http://dx.doi.org/10.1186/s12916-018-1095-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044028/
https://www.ncbi.nlm.nih.gov/pubmed/30001708
http://dx.doi.org/10.1186/s12916-018-1095-6

Ejemplares similares